

OncoTherapy Science, Inc.
Tella, Inc.
April 22, 2016

Commencement of “Neoantigen Dendritic Cells vaccine therapy”

OncoTherapy Science, Inc. (Head office: Kawasaki city, Kanagawa; President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) and Tella, Inc. (Head office: Shinjuku-ku, Tokyo; President & Representative Director: Yuichiro Yazaki; hereinafter, “Tella”) announce that they have agreed to tackle joint development of “Neoantigen Dendritic Cells vaccine therapy” (hereinafter, “Neoantigen DC therapy”) based on somatic mutation analysis of cancer. This joint development is positioned as one of the important business among “Cancer Precision Medicine Initiative” that OncoTherapy will pursue.

Neoantigen DC therapy is “an ultimate personalized medicine”, which provides patient-specific, cancer-specific vaccine utilizing not only each patient’s unique somatic mutation analysis but also his/her own dendritic cells. In terms of significant features, it induces very high immune reactions and is applicable to the great majority of cancer patients because of targeting their unique somatic mutations in cancer cells.

OncoTherapy, which advocates “Cancer Precision Medicine Initiative” based on systematic cancer immunopharmacogenomics, aims to establish the prediction system of the most appropriate molecular targeted drug based on result of analyzing each cancer patient and provide personalized cancer vaccine therapy, and launched the TCR analysis service business in September, 2015 as part of the Cancer Precision Medicine Initiative.

On the other hand, Tella, which has already established the Dendritic Cells vaccine therapy, attempts to merge its therapy with the cancer immunopharmacogenomics. Therefore, OncoTherapy and Tella have agreed to tackle jointly-developing Neoantigen DC therapy.

Neoantigen DC therapy is based on somatic mutations found in cancer cells and utilizes such mutations specific to cancer cells as therapeutic vaccine. The joint-development specifies Neoantigen (corresponding to a missense mutation observed in cancer cells), which is likely to induce cytotoxic T lymphocyte (CTL) response, based on genetic

mutations in cancer cells as well as HLA genotypes of each patient. We are planning to use neoantigen in combination with the DC vaccine therapy. Furthermore, the joint-development provides monitoring of therapeutic effect through TCR analysis of T lymphocytes induced by this treatment.

OncoTherapy and Tella provide this Neoantigen DC vaccine therapy to cancer patients, whose cancer cells have higher number of somatic mutations such as lung cancer and triple-negative breast cancer.